Sihuan Pharmaceutical Holdings Group Ltd. (HKG:0460)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 13.35B +153.1% |
| Revenue (ttm) | 2.30B +19.6% |
| Net Income | -88.36M |
| EPS | -0.01 |
| Shares Out | 9.08B |
| PE Ratio | n/a |
| Forward PE | 23.57 |
| Dividend | 0.02 (1.62%) |
| Ex-Dividend Date | Sep 26, 2025 |
| Volume | 46,945,319 |
| Average Volume | 43,062,928 |
| Open | 1.400 |
| Previous Close | 1.390 |
| Day's Range | 1.400 - 1.490 |
| 52-Week Range | 0.530 - 1.920 |
| Beta | 1.13 |
| RSI | 45.84 |
| Earnings Date | Mar 27, 2026 |
About HKG:0460
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthet... [Read more]
Financial Performance
In 2024, HKG:0460's revenue was 1.90 billion, an increase of 2.18% compared to the previous year's 1.86 billion. Losses were -216.66 million, 301.1% more than in 2023.
Financial numbers in CNY Financial StatementsNews
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
HONG KONG , June 27, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd. ("Xuanzhu Biopharm"),...